Clinical trials: Glioma Tumor Recurrence
Giant Cell Glioblastoma, Recurrent Glioblastoma
Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
This pilot early phase I trial studies the side effects of vaccine therapy in treating patients with glioblastoma that has come back.
- Conditions
- Giant Cell Glioblastoma, Recurrent Glioblastoma, Recurrent Gliosarcoma
- Trial name
- NCT03360708
- Testing
- Laboratory Biomarker Analysis, Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma
RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
The Investigators have demonstrated in preclinical studies that RNA liposomes activate APCs, induce antigen-specific T cell immunity, and can supplant DCs in a cell therapy model for HGG and have shown feasibility and activity of…
- Trial name
- RNA PRIME (NCT05660408)
- Testing
- pp65 RNA LP (DP1), pp65/tumor mRNA RNA-LP (DP2), Surgical Biopsy/Resection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Florida
Neurological Cancer
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
- Trial name
- NCT03922555
- Testing
- ASTX727
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma Multiforme
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
This trial is divided into two parts, a dose-escalation study (phase 1) and a randomized study (phase 2). The purpose of the dose-escalation study (phase 1) is to determine the safety, maximum tolerated dose (MTD), and efficacy…
- Trial name
- NCT01933815
- Testing
- TPI 287, Bevacizumab
- Where
- 9 sites in United States
- Volunteers
- 92 people
- Sponsor
- Cortice Biosciences, Inc.
DIPG, Brain Tumor, Pediatric, Recurrent
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
Although many children with brain tumours are successfully cured of their disease, a substantial proportion of patients suffer disease recurrence and require further treatment.
- Conditions
- DIPG, Brain Tumor, Pediatric, Recurrent, Brain Tumor, DIPG, Radiation Toxicity
- Trial name
- NCT04670016
- Testing
- This study does not include an intervention.
- Where
- 13 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Calgary
Glioblastoma, Gliosarcoma
Ph I Dasatinib + Erlotinib in Recurrent MG
Primary: To determine maximum tolerated dose \& dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG Secondary: To further evaluate safety \& tolerability of dasatinib + erlotinib To evaluate…
- Trial name
- NCT00609999
- Testing
- Erlotinib and Dasatinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Gliosarcoma
AMG 102 and Avastin for Recurrent Malignant Glioma
The primary purpose of the study is to assess the response rate of AMG 102 and Avastin treatment in subjects with advanced malignant glioma.
- Trial name
- NCT01113398
- Testing
- AMG 102, Avastin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Katy Peters
Brain and Central Nervous System Tumors
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells.
- Trial name
- NCT00074334
- Testing
- TGFa-PE38 immunotoxin, conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma Multiforme
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
This open-label, multicenter study will evaluate the safety and efficacy of RO5323441 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma.
- Trial name
- NCT01308684
- Testing
- RO5323441 + bevacizumab [Avastin], bevacizumab [Avastin]
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Glioblastoma, Gliosarcoma
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
- Trial name
- PD0332991 (NCT01227434)
- Testing
- PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Glioma, High Grade
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
This clinical trial is designed to evaluate the safety and efficacy of a universal mRNA vaccine targeting a panel of glioma-associated mutations in patients with recurrent or progressive high-grade glioma.
- Trial name
- NCT07306299
- Testing
- Glioma-related multi-target mRNA vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Ovarian Cancer
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Chimeric antigen receptor T cells (CAR-T) therapy has not yet been fully explored in solid tumors. Human epidermal growth factor receptor-2(HER2) is widely expressed in cancers.
- Conditions
- Breast Cancer, Ovarian Cancer, Lung Cancer, Gastric Cancer
- Trial name
- NCT02713984
- Testing
- Anti-HER2 CAR-T
- Where
- China
- Sponsor
- Zhi Yang
Glioblastoma Multiforme, Anaplastic Astrocytoma
AZD8055 for Adults With Recurrent Gliomas
Background: AZD8055 is an experimental cancer treatment drug that works by inhibiting a protein called mTOR, which is known to promote tumor cell and blood vessel growth and to control tumor s energy and nutrient levels.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Malignant Glioma
- Trial name
- NCT01316809
- Testing
- AZD8055
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas
Optico-chiasmatic gliomas have therapeutic feature since surgical resection plays a secondary role. Unlike other sites, many of these tumors are not amenable to complete resection either because of anatomical location, and…
- Trial name
- FLUVABREX (NCT02115074)
- Testing
- Fluvastatine, Celebrex
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Centre Oscar Lambret
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Recurrent Glioma, Solid Tumor
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT)…
- Trial name
- NCT04794972
- Testing
- GNC-039
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Recurrent Glioblastoma
Feasibility of Individualized Therapy for Recurrent Glioblastoma
The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion.
- Trial name
- NCT03681028
- Testing
- Individualized therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jennifer Clarke
Glioblastoma, Gliosarcoma
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
This partially randomized pilot phase I trial studies how much sapanisertib reaches the brain tumor and how well it works when given before and after surgery in treating patients with glioblastoma that has grown or come back and…
- Trial name
- NCT02133183
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors, Spinal Cord Tumors
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma
The goal of this clinical research study is to learn if lapatinib when given in combination with temozolomide can help to control ependymoma that has come back after treatment. The safety of this combination will also be studied.
- Trial name
- NCT00826241
- Testing
- Temozolomide, Lapatinib
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.